Keyphrases
Obese Patients
100%
Obesity
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Multiple Myeloma
100%
Melphalan
80%
Total Body Irradiation
60%
Progression-free Survival
60%
Morbid Obesity
40%
Overall Survival
40%
Body Mass Index
40%
Chemotherapy Dose
40%
Myeloma
20%
Improved Outcomes
20%
Chemotherapy
20%
Autologous Transplantation
20%
CIBMTR
20%
Reduced Dose
20%
Non-relapse Mortality
20%
Clinical Significance
20%
Patient Selection
20%
Overall Effect
20%
Overweight Patient
20%
High-dose Melphalan
20%
Melphalan Conditioning
20%
Common Strategies
20%
Medicine and Dentistry
Multiple Myeloma
100%
Autologous Hematopoietic Stem Cell Transplantation
100%
Melphalan
100%
Whole Body Radiation
60%
Progression Free Survival
60%
Hematopoietic Stem Cell Transplantation
40%
Conditioning
40%
Body Mass Index
40%
Overall Survival
40%
Drug Megadose
20%
Myeloma
20%
Autotransplantation
20%
Clinical Significance
20%
Biochemistry, Genetics and Molecular Biology
Autologous Hematopoietic Stem Cell Transplantation
100%
Melphalan
100%
Progression Free Survival
60%
Overall Survival
40%
Conditioning
40%
Body Mass
40%
Hematopoietic Stem Cell Transplantation
40%
Drug Megadose
20%
Autotransplantation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Melphalan
100%
Multiple Myeloma
100%
Chemotherapy
60%
Progression Free Survival
60%
Overall Survival
40%
Myeloma
20%